Tricyclic androgen receptor modulator compounds and methods

Abstract

Provided are non-steroidal tricyclic compounds that are modulators of androgen receptors and methods for making and using such compounds.

1 . A compound of the formula: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     wherein:
 R 1  is selected from among hydrogen, F, Cl, Br, I, NO 2 , OR 12 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 R 12 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl and C 1 -C 8  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 R 2  is selected from among hydrogen, F, Cl, Br, I, CH 3 , CF 3 , CHF 2 , CH 2 F, CF 2 Cl, CN, CF 2 OR 12 , CH 2 OR 12 , OR 12 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 R 13 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkenyl and C 2 -C 8  alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted; 
 R 3  through R 8  each independently is selected from among hydrogen, F, Cl, Br, I, OR 12 , NR 12 R 13 , SR 12 , SOR 12 , SO 2 R 12 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkynyl, C 2 -C 8  alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, hetero-alkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or 
 R 3  and R 5  taken together form a bond; or 
 R 5  and R 7  taken together form a bond; or 
 R 4  and R 6  taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted; or 
 R 6  and R 8  taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted; 
 R 9  and R 10  each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR 12 , NR 12 R 13 , C m (R 12 ) 2m OR 13 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 C(O)R 13 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted; 
 R 11  is selected from among hydrogen, F, Br, Cl, I, CN, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, OR 14 , NR 14 R 13 , SR 14 , CH 2 R 14 , C(O)R 14 , CO 2 R 14 , C(O)NR 14 R 13 , SOR 14  and SO 2 R 14 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 R 12  and R 13  each independently is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkenyl, C 2 -C 8  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; 
 R 14  is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, aryl, heteroaryl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted; 
 R 15  and R 16  each independently is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 W is O or S; 
 X is selected from among O, S and N{R 14 }; 
 Y is selected from among O, S, N{R 12 }, N{OR 12 } and CR 12 R 13 ; 
 Z is O or S; 
 m is 0, 1, or 2; and 
 n is 0, 1 or 2; 
 
     or pharmaceutically acceptable salts thereof. 
   
   
       2 . A compound of the formula: 
     
       
         
         
             
             
         
       
     
     wherein:
 R 1  is selected from among hydrogen, F, Cl, Br, I, NO 2 , OR 12 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 R 12 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl and C 1 -C 8  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 R 2  is selected from among hydrogen, F, Cl, Br, I, CH 3 , CF 3 , CHF 2 , CH 2 F, CF 2 Cl, CN, CF 2 OR 12 , CH 2 OR 12 , OR 12 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 R 13 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkenyl and C 2 -C 8  alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted; 
 R 3  through R 8  each independently is selected from among hydrogen, F, Cl, Br, I, OR 12 , NR 12 R 13 , SR 12 , SOR 12 , SO 2 R 12 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkynyl, C 2 -C 8  alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or 
 R 3  and R 5  taken together form a bond; or 
 R 5  and R 7  taken together form a bond; or 
 R 4  and R 6  taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted; or 
 R 6  and R 8  taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted; 
 R 9  and R 10  each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR 12 , NR 12 R 13 , C m (R 12 ) 2m OR 13 , SR 12 , SOR 12 , SO 2 R 12 , NR 12 C(O)R 13 , C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted; 
 R 11  is selected from among hydrogen, F, Br, Cl, I, CN, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, OR 14 , NR 14 R 13 , SR 14 , CH 2 R 14 , C(O)R 14 , CO 2 R 14 , C(O)NR 14 R 13 , SOR 14  and SO 2 R 14 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 R 12  and R 13  each independently is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, C 2 -C 8  alkenyl, C 2 -C 8  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; 
 R 14  is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, aryl, heteroaryl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted; 
 R 15  and R 16  each independently is selected from among hydrogen, C 1 -C 8  alkyl, C 1 -C 8  haloalkyl, C 1 -C 8  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; 
 W is O or S; 
 X is N{R 14 }; 
 Y is selected from among O, S, N{R 12 }, N{OR 12 } and CR 12 R 13 ; 
 Z is selected from among O, S and N{R 12 }; 
 m is 0, 1, or 2; and 
 n is 1; 
 
     or pharmaceutically acceptable salts thereof. 
   
   
       3 . The compound of  claim 1 , wherein R 1  is selected from among hydrogen, F, Cl, Br, I, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       4 . The compound of  claim 1 , wherein:
 R 2  is selected from among hydrogen, F, Cl, Br, CF 3 , CF 2 Cl, CF 2 H, CFH 2 , C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 2  is selected from among CF 2 OR 12 , CH 2 OR 12 , OR 12 , SR 12 , SOR 12 , SO 2 R 12  and NR 12 R 13 .   
   
   
       5 . The compound of  claim 1 , wherein:
 R 3  and R 4  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 3  and R 5  taken together form a bond; or   R 4  and R 6  taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       6 . The compound of  claim 1 , wherein:
 R 5  and R 7  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 5  and R 7  taken together form a bond.   
   
   
       7 . The compound of  claim 1 , wherein:
 R 6  and R 8  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or   R 6  and R 8  taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       8 . The compound of  claim 1 , wherein R 9  and R 10  each independently is selected from hydrogen, F, Cl, Br, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       9 . The compound of  claim 1 , wherein R 9  and R 10  each independently is selected from among hydrogen, F and CH 3 . 
   
   
       10 . The compound of  claim 1 , wherein R 11  is selected from among hydrogen, F, Br, Cl, CN, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, OR 14 , NR 14 R 13 , SR 14 , CH 2 R 14 , C(O)R 14 , CO 2 R 14 , C(O)NR 14 R 13 , SOR 14  and SO 2 R 14 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       11 . The compound of  claim 1 , wherein R 12  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted. 
   
   
       12 . The compound of  claim 1 , wherein R 13  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted. 
   
   
       13 . The compound of  claim 1 , wherein R 14  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       14 . The compound of  claim 1 , wherein X is N{R 14 } and n is 0 or 1. 
   
   
       15 . The compound of  claim 1 , wherein Y is O, S or N{R 12 }. 
   
   
       16 . The compound of  claim 1 , wherein Z is O. 
   
   
       17 . The compound of  claim 1 , wherein:
 R 1  is selected from among hydrogen, F, Cl, Br, I, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;   R 2  is selected from among hydrogen, F, Cl, Br, CF 3 , CF 2 Cl, CF 2 H, CFH 2 , C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; and   R 3  and R 4  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.   
   
   
       18 . The compound of  claim 17 , wherein:
 R 5  through R 8  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 6  and R 8  taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       19 . The compound of  claim 18 , wherein:
 R 9  and R 10  each independently is selected from among hydrogen, F, Cl, Br, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;   R 12  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; and   R 14  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.   
   
   
       20 . The compound of  claim 19 , wherein:
 W is O or S;   X is S or N{R 14 };   Y is O or S;   Z is O; and   n is 0 or 1.   
   
   
       21 . The compound of  claim 1 , wherein Y and W each independently is O or S. 
   
   
       22 . The compound of  claim 1 , wherein Y and W are each O. 
   
   
       23 . The compound of  claim 2 , wherein R 1  is selected from among hydrogen, F, Cl, Br, I, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       24 . The compound of  claim 2 , wherein:
 R 2  is selected from among hydrogen, F, Cl, Br, CF 3 , CF 2 Cl, CF 2 H, CFH 2 , C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.   
   
   
       25 . The compound of  claim 2 , wherein:
 R 3  and R 4  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 3  and R 5  taken together form a bond; or   R 4  and R 6  taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       26 . The compound of  claim 2 , wherein:
 R 5  and R 7  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 5  and R 7  taken together form a bond.   
   
   
       27 . The compound of  claim 2 , wherein:
 R 6  and R 8  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or   R 6  and R 8  taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       28 . The compound of  claim 2 , wherein R 9  and R 10  each independently is selected from hydrogen, F, Cl, Br, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       29 . The compound of  claim 2 , wherein R 11  is selected from among hydrogen, F, Br, Cl, CN, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, OR 14 , NR 14 R 13 , SR 14 , CH 2 R 14 , C(O)R 14 , CO 2 R 14 , C(O)NR 14 R 13 , SOR 14  and SO 2 R 14 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       30 . The compound of  claim 2 , wherein R 12  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted. 
   
   
       31 . The compound of  claim 2 , wherein R 13  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted. 
   
   
       32 . The compound of  claim 2 , wherein R 14  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted. 
   
   
       33 . The compound of  claim 2 , wherein Y is O, S or N{R 12 }. 
   
   
       34 . The compound of  claim 2 , wherein Z is O or N{R 12 }. 
   
   
       35 . The compound of  claim 2 , wherein:
 R 1  is selected from among hydrogen, F, Cl, Br, I, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;   R 2  is selected from among hydrogen, F, Cl, Br, CF 3 , CF 2 Cl, CF 2 H, CFH 2 , C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; and   R 3  and R 4  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.   
   
   
       36 . The compound of  claim 35 , wherein:
 R 5  through R 8  each independently is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or   R 6  and R 8  taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted.   
   
   
       37 . The compound of  claim 36 , wherein:
 R 9  and R 10  each independently is selected from among hydrogen, F, Cl, Br, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;   R 12  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl and C 1 -C 6  heteroalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; and   R 14  is selected from among hydrogen, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  heteroalkyl, C(O)R 15 , CO 2 R 15  and C(O)NR 15 R 16 , wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.   
   
   
       38 . The compound of  claim 37 , wherein:
 W is O or S;   Y is O or S; and   Z is O or N{R 12 }.   
   
   
       39 . A compound selected from among:
 5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;   5,6,7,8-Tetrahydro-7,7-diethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;   7,8-Dihydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;   5,6,7,8-Tetrahydro-7,7,8-trimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;   8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]-quinolin-2(1H)-one;   5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-f]-quinolin-2(1H)-one,   8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethyl-pyridino[3,2-f]quinolin-2(1H)-one;   (±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;   (±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-ethyl-4-trifluoromethylcyclopentano[i]pyrrolo-[2,3-g]quinolin-2(1H)-one;   (±)-7,8-Dihydro-7,8-cis-dimethyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;   6-(2,2,2-Trifluoroethyl)-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[i]pyrrolo-[2,3-g]-quinolin-2(1H)-one;   7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]-quinolin-2(1H)-one;   4-Trifluoromethyl-6,7-dihydro-7,7,9-trimethyl-pyrido[2,3-g]quinolin-2(1H)-one;   8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-f]-quinolin-2(1H)-one;   4,5,7-Tri(trifluoromethyl)pyrido[3,2-f]quinolin-2(1H)-one;   5,7-Bis(trifluoromethyl)pyrido[3,2-f]quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-7,8-dihydro-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]-quinolin-2(1H)-one;   4-Trifluoromethyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;   4-Trifluoromethyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]-quinolin-2(1H)-one;   6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2-(1H)-one;   6,7-Dihydro-8,8,10-trimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-4-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (±)-7,8-Dihydro-8-ethyl-4-methyl-6H-pyrano[2,3-f]quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (−)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (+)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]-quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]-quinolin-2(1H)-one;   (±)-6,7-Dihydro-6-ethyl-2,4-bis(trifluoromethyl)-8H-pyrano[3,2-g]quinoline;   6,8,8-Trimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;   6-Ethyl-8,8-dimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;   7,8-Dihydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;   6-(2,2,2-Trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;   8-Chloro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;   8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]-quinolin-2(1H)-one;   5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-f]-quinolin-2(1H)-one;   8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethyl-pyridino[3,2-f]quinolin-2(1H)-one;   (±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;   (±)-7,8-Dihydro-7,8-cis-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6H-pyrrolo-[2,3-g]quinolin-2(1H)-one;   6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[i]pyrrolo-[2,3-g]-quinolin-2(1H)-one;   7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]-quinolin-2(1H)-one;   8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-f]-quinolin-2(1H)-one;   4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido-[2,3-g]-quinolin-2(1H)-one;   6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;   (−)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one; and   (+)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one.   
   
   
       40 . A pharmaceutical composition, comprising:
 a pharmaceutically acceptable carrier; and   a compound of  claim 1 .   
   
   
       41 . A method of treating an individual having a condition mediated through an androgen receptor, comprising administering to the individual a pharmaceutically effective amount of a compound of  claim 1 , wherein the condition is selected from among acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers. 
   
   
       42 . A method of treating hormone-dependent cancer, comprising administering to a patient in need thereof an effective amount of a compound of  claim 1 . 
   
   
       43 . A method of providing a therapy to an individual, comprising:
 administering to the individual a pharmaceutically effective amount of a compound of  claim 1  that is an androgen receptor agonist, wherein the therapy is selected from among hormone replacement therapy, stimulation of hematopoiesis, male contraception and stimulation of libido.   
   
   
       44 . A pharmaceutical composition, comprising:
 a pharmaceutically acceptable carrier; and   a compound of  claim 2 .   
   
   
       45 . A method of treating an individual having a condition mediated through an androgen receptor, comprising administering to the individual a pharmaceutically effective amount of a compound of  claim 2 , wherein the condition is selected from among acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers. 
   
   
       46 . A method of treating hormone-dependent cancer, comprising administering to a patient in need thereof an effective amount of a compound of  claim 2 . 
   
   
       47 . A method of providing a therapy to an individual, comprising:
 administering to the individual a pharmaceutically effective amount of a compound of  claim 2  that is an androgen receptor agonist, wherein the therapy is selected from among hormone replacement therapy, stimulation of hematopoiesis, male contraception and stimulation of libido.